MEK inhibitors
Erasca Starts Tissue-Agnostic Trial of RAF/MEK Combination Therapy
The firm will study the activity of its pan-RAS inhibitor naporafenib with Novartis' MEK inhibitor Mekinist in RAS Q61X-mutated solid tumors.
Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients
Premium
Results from the DreamSeq trial showed that more melanoma patients who received frontline immunotherapy were alive at two years compared to frontline targeted therapy.
MMRF Data Fuels Greater Understanding of Multiple Myeloma Drug Resistance, Mutational Landscape
Premium
The nonprofit hopes its longitudinal studies and clinical trials will help move targeted therapies into upfront therapy for multiple myeloma.
The combinations being studied in a master protocol trial were selected based on research from MSK suggesting the value of blocking KRAS mutations and ERK pathway signaling.
SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance
Genomic sequencing on 733 HER2-positive advanced breast cancer patients revealed mechanisms of anti-HER2 treatment resistance and potential therapeutic solutions.